Covered recipient · General Payments record
JAMES HENDRICKS LEWIS
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$215,442.85
152 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $135,620.50 | 24 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69,882.00 | 21 |
| Travel and Lodging | $6,389.63 | 39 |
| Food and Beverage | $3,550.72 | 68 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $82,780.16 | 93 |
| Daiichi Sankyo Inc. | $70,416.62 | 29 |
| PFIZER INC. | $21,150.00 | 3 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $18,300.00 | 1 |
| AbbVie, Inc. | $6,317.95 | 11 |
| Novartis Pharma AG | $5,750.00 | 2 |
| SANOFI US SERVICES INC. | $3,501.75 | 1 |
| HRA Pharma | $2,400.00 | 1 |
| Otsuka Pharmaceutical Co., Ltd. | $1,662.50 | 2 |
| VERTEX PHARMACEUTICALS INCORPORATED | $1,125.00 | 2 |
| GlaxoSmithKline, LLC. | $1,040.00 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | $875.00 | 1 |
| Alexion Pharmaceuticals, Inc. | $97.87 | 4 |
| Intercept Pharmaceuticals, Inc. | $26.00 | 1 |
Page 4 of 4; records 151–152 of 152 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES HENDRICKS LEWIS
NPI 1396745212 · CMS profile ID 63334
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
WASHINGTON, DC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–152 of 152 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–152 of 152 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–152 of 152 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JAMES HENDRICKS LEWIS, NPI 1396745212, CMS profile ID 63334, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–152 of 152 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396745212?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
152 matching records · $215,442.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–152 of 152.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $26.50 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681552511 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $18,300.00 | 01/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696054727 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $60,841.50 | 26 |
| PY2025 | Principal investigator | $8,850.00 | 2 |
| PY2024 | Recipient | $75,187.50 | 17 |
| PY2024 | Principal investigator | $15,802.50 | 4 |
| PY2023 | Recipient | $83,326.52 | 16 |
| PY2023 | Principal investigator | $6,312.50 | 5 |
| PY2022 | Recipient | $12,745.42 | 9 |
| PY2022 | Principal investigator | $675.00 | 1 |
| PY2021 | Recipient | $3,125.00 | 2 |
| PY2021 | Principal investigator | $5,850.00 | 5 |
| PY2020 | Recipient | $4,050.00 | 2 |
| PY2020 | Principal investigator | $19,494.00 | 14 |
| PY2019 | Principal investigator | $18,271.72 | 8 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
28 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Boehringer Ingelheim International GmbH | $2,500.00 | 12/22/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779512 |
| Recipient | Intercept Pharmaceuticals, Inc. | $1,833.28 | 12/15/2025 | Covered Recipient Physician | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248170792 |
| Recipient | Intercept Pharmaceuticals, Inc. | $166.66 | 11/15/2025 | Covered Recipient Physician | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248170794 |
| Recipient | Boehringer Ingelheim International GmbH | $2,600.00 | 10/23/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779510 |
| Recipient | Intercept Pharmaceuticals, Inc. | $166.66 | 10/15/2025 | Covered Recipient Physician | FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) | No dispute reported | 06/30/2026 | 1248170790 |
| Recipient | Boehringer Ingelheim International GmbH | $3,900.00 | 09/19/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779508 |
| Recipient | Intercept Pharmaceuticals, Inc. | $499.98 | 09/15/2025 | Covered Recipient Physician | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248170788 |
| Recipient | Boehringer Ingelheim International GmbH | $2,600.00 | 08/18/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779506 |
| Recipient | Intercept Pharmaceuticals, Inc. | $1,000.00 | 08/15/2025 | Covered Recipient Physician | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248170786 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,375.00 | 08/07/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223263154 |
| Recipient | Boehringer Ingelheim International GmbH | $4,600.00 | 07/28/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779504 |
| Recipient | ABBVIE INC. | $1,150.00 | 07/23/2025 | Covered Recipient Physician | Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity in Adult Participants With Migraine | No dispute reported | 06/30/2026 | 1202399649 |
| Recipient | ABBVIE INC. | $2,550.00 | 07/14/2025 | Covered Recipient Physician | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine | No dispute reported | 06/30/2026 | 1202399645 |
| Recipient | Ipsen Bioscience Inc. | $1,375.00 | 07/04/2025 | Covered Recipient Physician | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (ELONSEN) | No dispute reported | 06/30/2026 | 1176546813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,200.00 | 06/16/2025 | Non-covered Recipient Entity James H. Lewis, LLC | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220673326 |
| Recipient | Boehringer Ingelheim International GmbH | $5,400.00 | 06/16/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779502 |
| Recipient | Boehringer Ingelheim International GmbH | $4,800.00 | 06/02/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779500 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,125.00 | 05/16/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223263152 |
| Recipient | Intercept Pharmaceuticals, Inc. | $166.66 | 05/15/2025 | Covered Recipient Physician | FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) | No dispute reported | 06/30/2026 | 1248170784 |
| Recipient | Intercept Pharmaceuticals, Inc. | $833.32 | 04/15/2025 | Covered Recipient Physician | FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) | No dispute reported | 06/30/2026 | 1248170782 |
| Recipient | Intercept Pharmaceuticals, Inc. | $166.66 | 03/12/2025 | Covered Recipient Physician | FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH) | No dispute reported | 06/30/2026 | 1248170780 |
| Recipient | Boehringer Ingelheim International GmbH | $9,000.00 | 02/17/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779498 |
| Principal investigator 1 | Eli Lilly and Company | $7,650.00 | 01/21/2025 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187872503 |
| Recipient | Boehringer Ingelheim International GmbH | $400.00 | 01/20/2025 | Covered Recipient Physician | A Phase III, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in patients with obesity disease in Japanese | No dispute reported | 06/30/2026 | 1220779492 |
| Recipient | Boehringer Ingelheim International GmbH | $600.00 | 01/20/2025 | Covered Recipient Physician | A Phase III, randomized, double-blind, parallel-group, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in Chinese participants with a BMI >=28 kg/m2 or BMI >=24 kg/m2 with at least one weight-related complication | No dispute reported | 06/30/2026 | 1220779494 |
| Recipient | Boehringer Ingelheim International GmbH | $9,600.00 | 01/15/2025 | Covered Recipient Physician | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220779496 |
| Recipient | Intercept Pharmaceuticals, Inc. | $1,833.28 | 01/08/2025 | Covered Recipient Physician | Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | No dispute reported | 06/30/2026 | 1248170778 |
| Recipient | Boehringer Ingelheim International GmbH | $600.00 | 01/06/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220779490 |